King’s College London
The Gene Therapy Vector Facility (GTVF) at King’s College London is an MHRA licenced GMP viral-vector manufacturing facility, supporting the development of advanced therapies for early-stage clinical trials. With over 20 years of experience and more than 120 GMP viral-vector batches delivered, GTVF offers cost-effective, reliable manufacturing for academic and commercial partners.
We manufacture lentiviral (LV), retroviral (RV), and adeno-associated viral (AAV) vectors, offering both drug substance and drug product production. We have platform manufacturing processes available and a large process development team to support all areas of client’s projects. Packaging plasmids are available for use, helping to streamline timelines.
Operating from MHRA-accredited GMP cleanrooms with team of 60 specialist, GTVF delivers comprehensive project support from early technology transfer and process development through clinical manufacture, including regulatory and CMC expertise. Our model is designed to bridge the gap between the bench and the clinic, providing competitive, accessible GMP vector manufacturing without the commercial CDMO price tag.
GTVF partners with academic institutions, charities, biotech’s, and pharmaceutical companies to accelerate the translation of promising cell and gene therapies to patients.
